Navigation Links
Ground Zero Pharmaceuticals, Inc. (GZP) Announces Expansion of Oncology Programs for Its Clients
Date:10/27/2011

IRVINE, Calif., Oct. 27, 2011 /PRNewswire/ -- GZP is announcing expansion of its client oncology programs, from strategic and regulatory consulting through product development and clinical trial execution, of pharmaceutical and biological therapies.  These include treatment vaccines, somatic cell and gene therapies, and novel small molecules.  Senior associates with oncology expertise in nonclinical, manufacturing, and clinical development provide clients with hands-on guidance throughout the FDA regulatory review process.  Firms in the US, Europe and Australia are actively working with GZP, in Phase 1 through Phase 3 clinical trials.

Dr. Evan B. Siegel, GZP's CEO, will be at BioEurope in Dusseldorf and BioMalaysia in Kuala Lumpur, and will be pleased to meet with interested parties during either meeting's formal partnering or by individual arrangement.

In 2011, GZP increased its global client base at all development phases across therapeutic areas such as oncology and neurological disease.  The firm created and submitted several INDs and SPAs and facilitated many pre-IND and mid-phase meetings with the FDA leading to rapid movement of client programs.  GZP believes that early, frequent, and creative FDA communication leads to more successful product development and attracts investors in today's difficult financial climate.

According to Evan Siegel, "We are pleased that the disappointing recovery from the global financial crisis has not diminished the entry of new intellectual property into the biotechnology and pharmaceutical space.  Our clients are determined to be successful and we are honored to provide support towards that end.  The expansion of our business is attributable to their trust in GZP, due to the excellence of our team which maintains an integrated and client-specific approach to deliver the highest quality services."

Based in Irvine, Ground Zero Pharmaceuticals, Inc. is a regulatory affairs, product development, and clinical consulting firm providing strategic and tactical services to the pharmaceutical, biotechnology and medical device industries.  These include regulatory representation and submissions, medical consulting and monitoring, preclinical planning, auditing of clinical, nonclinical and manufacturing sites, medical writing, chemistry, manufacturing and controls consulting, clinical trial execution, data management, biostatistics, and project management.  GZP has resources throughout the US, Canada, Australia and Europe, and a wholly owned subsidiary in Brisbane and Melbourne, Australia.

For further information please contact Ms. Tisha Templeton, Senior Vice President, Finance and Operations, Ground Zero Pharmaceuticals, Inc., +1-949-419-6136, fax, +1-949-861-9797, ttempleton@groundzerous.com.

Web Site: http://www.groundzerous.com


'/>"/>
SOURCE Ground Zero Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharmaceutical Industry Leaders to Tackle Groundbreaking Challenges, Opportunities for Pharma & Biotech at Elite Event
2. Rottenstein Law Group Heeds Groundswell of Grievances Against Manufacturers of Defective, Dangerous Hip Replacement Devices
3. Femasys and Norgenix Announce Distribution Agreement for Groundbreaking New Device for Infertility Diagnosis
4. Groundbreaking Report Details the New $80 Billion Accountable-Care Market
5. International Dyslexia Association Announces Groundbreaking Parent Membership Initiative in Response to 40,000 Annual Inquiries
6. Newborn Possibilities Fund Awards Grant to Georgia Health Sciences University Foundation to Support Groundbreaking Pediatric Research
7. Glenveigh Medical and Monica Healthcare Announce Distribution Agreement for Groundbreaking FDA Cleared Wireless Fetal Monitoring System
8. SinoFresh Healthcare, Inc. Takes Groundbreaking Products to Europe
9. Emerging Markets Are Gaining Ground in Medical Technology Innovation; U.S. Maintains Lead, Finds PwCs Medical Technology Innovation Scorecard
10. Groundbreaking Study Showed Bayers Advantage Multi® for Dogs (imidacloprid + moxidectin) Topical Solution was the only Heartworm Preventive Tested That Demonstrated 100 Percent Efficacy against the Challenging MP3 Strain
11. Pharma Industry Leaders to Reveal Hottest, Latest Trends for Pharma & Biotech at Groundbreaking Event
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/27/2017)... Israel and NEW YORK , Sept. 27, ... with mobile health and big data solutions, today announced that its MyDario ... Please check your local TV listings for when The Dr. Oz Show ... ... season this month. ...
(Date:9/23/2017)... Pa. , Sept. 22, 2017 Janssen ... a complete response letter from the U.S. Food and ... seeking approval of sirukumab for the treatment of moderately ... letter indicates additional clinical data are needed to further ... moderately to severely active RA. ...
(Date:9/19/2017)... Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that uses ... today:   ... Jim ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led R&D and business ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance ... care insurance companies have a waiver for care if the client has a cognitive ... the family pays for care, is often waived, so the benefits from their insurance ...
(Date:10/13/2017)... Texas (PRWEB) , ... October 13, 2017 , ... Yisrayl ... this week that explains one of the most popular and least understood books in ... like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian history ... The Brink” is the creation of published author, William Nowers. Captain Nowers and ... WWII veteran, he spent thirty years in the Navy. Following his career as ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... the demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults ... tested to meet the highest standard. , These products are also: Gluten ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the ... to develop to enable prevention of a major side effect of chemotherapy in ... in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a ...
Breaking Medicine News(10 mins):